INSILICO (03696.HK): ISM9528 Begins First-in-Human Dosing
NewTimeSpace News: On 17 November 2026, InSilico Medicine Cayman TopCo (stock code: 3696) announced on a voluntary basis that it has completed the first-in-human dosing of ISM9528, a potential first-in-class non-opioid pain candidate discovered in Abu Dhabi, just four months after its preclinical candidate (PCC) nomination.
According to the announcement, the exploratory trial evaluates the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered ISM9528 in healthy adult volunteers. As the study proceeds, the Company may submit additional dossiers to the relevant authorities and expand the trial, subject to regulatory authorisation.
ISM9528 was nominated as a PCC in July 2026 by the Company's Abu Dhabi team, becoming its 31st PCC since 2021 and the second to emerge from its UAE research effort. In preclinical studies, it showed favourable efficacy versus standard of care in validated models of acute postsurgical pain and neuropathic pain, with favourable safety properties and rapid systemic absorption plus excellent blood-brain barrier permeability supporting a favourable DMPK profile.
- INSILICO (03696.HK) signs AI drug R&D pact with Luoxin Pharmaceutical
- INSILICO (03696.HK): First-in-Human ISM6331 Data Show 40% ORR in 130mg Mesothelioma Cohort
- ILUVATAR COREX (09903.HK): banking facilities over RMB12 billion granted, over 80% unutilized, supporting business expansion
- INSILICO (03696.HK): Servier AI drug discovery milestone hit
- INSILICO (03696.HK): Nominates ISM9546 as 35th Preclinical Candidate